Akari Therapeutics' Preclinical Findings Highlight the Promise of Its Innovative ADC Spliceosome Modulating Agent, PH1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Source: Globenewswire
Akari Therapeutics' ADC Payload PH1: Preclinical data shows that Akari's novel antibody drug conjugate (ADC) payload, PH1, can effectively suppress the AR-V7 receptor, which is linked to the progression of hormone-refractory prostate cancer, addressing a significant unmet need in treatment options.
Potential for Combination Therapy: PH1 demonstrated efficacy both as a standalone treatment and in combination with existing therapies like Xtandi and Erleada, suggesting it could be developed as a first-line combination therapy to combat resistance in prostate cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
